Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVJF) Return on Sales (2016 - 2025)

Historic Return on Sales for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to 0.15%.

  • Teva Pharmaceutical Industries' Return on Sales rose 2100.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.09%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 0.08% for FY2025, which is 2000.0% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Return on Sales stood at 0.15% for Q4 2025, which was up 2100.0% from 0.1% recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Return on Sales ranged from a high of 0.15% in Q4 2025 and a low of 0.4% during Q4 2023
  • Over the past 5 years, Teva Pharmaceutical Industries' median Return on Sales value was 0.01% (recorded in 2021), while the average stood at 0.05%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 12000bps in 2021, then plummeted by -3100bps in 2022.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Return on Sales stood at 0.04% in 2021, then plummeted by -833bps to 0.34% in 2022, then dropped by -17bps to 0.4% in 2023, then soared by 84bps to 0.07% in 2024, then soared by 325bps to 0.15% in 2025.
  • Its Return on Sales was 0.15% in Q4 2025, compared to 0.1% in Q3 2025 and 0.07% in Q2 2025.